In a double-blind, placebo-controlled phase 2 study, autologous DC vaccine loaded with glioblastoma-stem-cell-like lines (GSC) prolonged OS in the IDH1-wildtype TERT-mutant and B7-H4 low expression newly-diagnosed GBM patients, with increasing levels of plasma CCL22 and IFN-γ [92]. This evidence concerns the gene CCL22 and glioblastoma.